Skye Bioscience
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Skye Bioscience generated cash of -$13,952,178, which is less than the previous year. Cash used in financing activities reached the amount of $16,443,270 last year. Net change in cash is therefore $9,087,548.
Cash Flow
| 2014 | -1.75M | -23.26K | 1.98M |
|---|---|---|---|
| 2015 | -3.72M | -1.98K | 6.74M |
| 2016 | -3.55M | -11.11K | 407.66K |
| 2017 | -3.29M | -19.65K | 3.51M |
| 2018 | -3.94M | -4.38K | 5.54M |
| 2019 | -6.02M | 0 | 6.00M |
| 2020 | -6.05M | -7.23K | 6.70M |
| 2021 | -6.47M | -90.86K | 13.07M |
| 2022 | -12.74M | 5.21M | -208.79K |
| 2023 | -13.95M | 6.59M | 16.44M |
SKYE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.24M | 8.98M | 2.47M | 1.83M | 1.85M | 264.38K | 64.82K | 3.22M | 207.33K | 0 |
Operating activities | ||||||||||
Net income | -37.64M | -19.48M | -8.52M | -6.56M | 1.05M | -19.19M | -3.09M | -3.17M | -4.84M | -2.73M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 124.25K | 114.99K | 34.13K | 1.87K | 1.46K | 1.54K | 8.03K | 14.91K | 9.95K | 1.90K |
Stock-based compensation expense | 987.51K | 629.03K | 869.20K | 302.74K | 680.45K | 674.96K | 608.67K | 706.36K | 414.34K | 10.77K |
| Deferred income tax benefit | 987.51K | 629.03K | 869.20K | 302.74K | 680.45K | 674.96K | 608.67K | 706.36K | 414.34K | 10.77K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -701.28K | 799.74K | 518.63K | 241.56K | 134.21K | -85.32K | -173.72K | 149.29K | -274.14K | 407.34K |
Cash generated by operating activities | -13.95M | -12.74M | -6.47M | -6.05M | -6.02M | -3.94M | -3.29M | -3.55M | -3.72M | -1.75M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -12.55K | -28.06K | -90.86K | -7.23K | 0 | -4.38K | -19.65K | -11.11K | -1.98K | -23.26K |
Acquisitions Net | 1.07M | 5.30M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 6.59M | 5.21M | -90.86K | -7.23K | 0 | -4.38K | -19.65K | -11.11K | -1.98K | -23.26K |
Financing activities | ||||||||||
Common Stock Issued | 11.73M | 1.96K | 6.06M | 6.08M | 1.91M | 9.79K | 187.55K | 50K | 721.02K | 1.98M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 4.70M | -210.76K | 0 | -566.7K | 5.19K | 0 | 500K | 0 | 0 | 0 |
Cash used in financing activities | 16.44M | -208.79K | 13.07M | 6.70M | 6.00M | 5.54M | 3.51M | 407.66K | 6.74M | 1.98M |
Net Change In Cash | 9.08M | -7.73M | 6.51M | 639.46K | -23.37K | 1.59M | 195.13K | -3.15M | 3.01M | 207.33K |
Cash at end of period | 10.33M | 1.24M | 8.98M | 2.47M | 1.83M | 1.85M | 259.95K | 64.82K | 3.22M | 207.33K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |